THE RESULTS: Drugmaker Pfizer’s results for the first quarter missed analysts’ expectations, as generic competition cut sales by 9 percent to $13.5 billion. Net income jumped 53 percent, but only because of a one-time gain in the quarter and big charges a year earlier.
THE REACTION: Between the weak results and Pfizer lowering its profit and revenue forecast for the year, investors drove down shares by an unusually steep 4.5 percent.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.